X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15797) 15797
Book Review (4726) 4726
Publication (1016) 1016
Newsletter (650) 650
Book / eBook (196) 196
Book Chapter (62) 62
Conference Proceeding (40) 40
Newspaper Article (19) 19
Dissertation (8) 8
Magazine Article (8) 8
Reference (6) 6
Trade Publication Article (3) 3
Presentation (2) 2
Report (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14820) 14820
humans (13441) 13441
female (7354) 7354
oncology (6941) 6941
male (5945) 5945
chemotherapy (5201) 5201
cancer (4931) 4931
middle aged (4663) 4663
adult (4202) 4202
animals (4061) 4061
antineoplastic combined chemotherapy protocols - therapeutic use (4002) 4002
aged (3684) 3684
antineoplastic agents - therapeutic use (2957) 2957
antineoplastic agents, alkylating - administration & dosage (2846) 2846
treatment outcome (2794) 2794
antineoplastic agents (2722) 2722
antimitotic agents (2253) 2253
care and treatment (2210) 2210
pharmacology & pharmacy (2152) 2152
hematology (2087) 2087
antineoplastic agents, alkylating - therapeutic use (1914) 1914
mice (1897) 1897
antineoplastic agents - administration & dosage (1894) 1894
combined modality therapy (1741) 1741
research (1711) 1711
cyclophosphamide (1694) 1694
cyclophosphamide - administration & dosage (1691) 1691
medicine & public health (1638) 1638
antineoplastic agents - adverse effects (1614) 1614
antineoplastic combined chemotherapy protocols - adverse effects (1597) 1597
neoplasms - drug therapy (1570) 1570
therapy (1554) 1554
antineoplastic agents - pharmacology (1550) 1550
dacarbazine - analogs & derivatives (1346) 1346
antineoplastic agents, alkylating - adverse effects (1328) 1328
drug therapy (1300) 1300
dose-response relationship, drug (1298) 1298
prognosis (1278) 1278
antineoplastic combined chemotherapy protocols - administration & dosage (1250) 1250
health aspects (1235) 1235
adolescent (1213) 1213
analysis (1191) 1191
disease-free survival (1173) 1173
temozolomide (1158) 1158
tumors (1154) 1154
drug administration schedule (1150) 1150
brain neoplasms - drug therapy (1130) 1130
cell line, tumor (1094) 1094
retrospective studies (1090) 1090
aged, 80 and over (1076) 1076
radiotherapy (1070) 1070
breast neoplasms - drug therapy (1045) 1045
abridged index medicus (1009) 1009
child (1003) 1003
survival analysis (975) 975
apoptosis (966) 966
survival rate (949) 949
toxicity (910) 910
transplantation (910) 910
survival (902) 902
time factors (896) 896
rats (881) 881
follow-up studies (878) 878
cisplatin (855) 855
neoplasm staging (852) 852
melphalan - administration & dosage (847) 847
clinical trials as topic (841) 841
doxorubicin - administration & dosage (834) 834
cisplatin - administration & dosage (816) 816
dacarbazine - administration & dosage (800) 800
hematology, oncology and palliative medicine (779) 779
phase-ii trial (777) 777
dosage and administration (772) 772
risk factors (764) 764
breast cancer (748) 748
dacarbazine - therapeutic use (743) 743
antineoplastic agents, alkylating - pharmacology (739) 739
surgery (722) 722
trial (718) 718
multiple myeloma - drug therapy (704) 704
glioblastoma (684) 684
phase-ii (683) 683
child, preschool (675) 675
article (665) 665
apoptosis - drug effects (652) 652
drug therapy, combination (648) 648
drug resistance, neoplasm (638) 638
drugs (636) 636
breast-cancer (618) 618
clinical neurology (618) 618
remission induction (617) 617
glioblastoma - drug therapy (612) 612
multiple myeloma (599) 599
leukemia (596) 596
ovarian neoplasms - drug therapy (594) 594
cyclophosphamide - adverse effects (590) 590
chemotherapy, adjuvant (588) 588
clinical trials (588) 588
pharmacokinetics (586) 586
lung neoplasms - drug therapy (578) 578
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (150) 150
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Online Resources - Online (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Chemistry (A D Allen) - Stacks (3) 3
Gerstein Science - Circulation Desk (2) 2
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16192) 16192
Japanese (107) 107
French (104) 104
German (87) 87
Russian (84) 84
Spanish (30) 30
Italian (25) 25
Chinese (21) 21
Polish (13) 13
Hungarian (9) 9
Czech (6) 6
Lithuanian (4) 4
Norwegian (4) 4
Ukrainian (4) 4
Dutch (3) 3
Hebrew (3) 3
Swedish (3) 3
Bulgarian (2) 2
Danish (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatric Blood & Cancer, ISSN 1545-5009, 01/2014, Volume 61, Issue 1, pp. 53 - 67
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1873 - 1883
Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based... 
Internal Medicine | BENDAMUSTINE | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CLL | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | MONOCLONAL-ANTIBODIES | ELDERLY-PATIENTS | FLUDARABINE | HUMAN CD20 | Age Distribution | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Chlorambucil - adverse effects | Prospective Studies | Chlorambucil - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Aged, 80 and over | Adult | Female | Chlorambucil - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Distribution | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antineoplastic Agents, Alkylating - adverse effects | Chlorambucil | Medical colleges | Hospitals | Comorbidity | United Kingdom | Product development | India | Medical research | Flow cytometry | Immunoglobulins | Medical imaging | Laboratories | Cytotoxicity | Infections | Ovarian cancer | Bone marrow | Drug dosages | Age | Binding sites | Geriatrics | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2517 - 2526
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 12, pp. 1325 - 1333
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article